EA201101286A1 - Композиции биодоступных капсул некристаллического соединения альфа-(n-сульфонамидо)ацетамина - Google Patents
Композиции биодоступных капсул некристаллического соединения альфа-(n-сульфонамидо)ацетаминаInfo
- Publication number
- EA201101286A1 EA201101286A1 EA201101286A EA201101286A EA201101286A1 EA 201101286 A1 EA201101286 A1 EA 201101286A1 EA 201101286 A EA201101286 A EA 201101286A EA 201101286 A EA201101286 A EA 201101286A EA 201101286 A1 EA201101286 A1 EA 201101286A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- crystallic
- acetamine
- sulphonamido
- capsules
- bio
- Prior art date
Links
- 239000002775 capsule Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
- 229920001223 polyethylene glycol Polymers 0.000 abstract 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 2
- XEAOPVUAMONVLA-QGZVFWFLSA-N Avagacestat Chemical compound C=1C=C(Cl)C=CC=1S(=O)(=O)N([C@H](CCC(F)(F)F)C(=O)N)CC(C(=C1)F)=CC=C1C=1N=CON=1 XEAOPVUAMONVLA-QGZVFWFLSA-N 0.000 abstract 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 abstract 1
- 239000007963 capsule composition Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229920001531 copovidone Polymers 0.000 abstract 1
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 abstract 1
- 229920002689 polyvinyl acetate Polymers 0.000 abstract 1
- 239000011118 polyvinyl acetate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16906109P | 2009-04-14 | 2009-04-14 | |
| PCT/US2010/030862 WO2010120755A1 (en) | 2009-04-14 | 2010-04-13 | Bioavailable capsule compositions of amorphous alpha-(n-sulfonamido)acetamide compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201101286A1 true EA201101286A1 (ru) | 2012-04-30 |
Family
ID=42235859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201101286A EA201101286A1 (ru) | 2009-04-14 | 2010-04-13 | Композиции биодоступных капсул некристаллического соединения альфа-(n-сульфонамидо)ацетамина |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8252821B2 (enExample) |
| EP (1) | EP2419090B1 (enExample) |
| JP (1) | JP2012524092A (enExample) |
| KR (1) | KR20120022766A (enExample) |
| CN (1) | CN102395361A (enExample) |
| AR (1) | AR076305A1 (enExample) |
| AU (1) | AU2010236602A1 (enExample) |
| BR (1) | BRPI1015483A2 (enExample) |
| CA (1) | CA2758847A1 (enExample) |
| EA (1) | EA201101286A1 (enExample) |
| MX (1) | MX2011010514A (enExample) |
| NZ (1) | NZ595335A (enExample) |
| TW (1) | TW201041609A (enExample) |
| WO (1) | WO2010120755A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ533603A (en) | 2001-12-20 | 2007-02-23 | Bristol Myers Squibb Co | Alpha-(N-sulphonamido)acetamide derivatives as beta-amyloid inhibitors used for treating Alzheimer's Disease and Down's syndrome |
| US8044077B2 (en) | 2009-03-19 | 2011-10-25 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production |
| US7977362B2 (en) | 2009-03-20 | 2011-07-12 | Bristol-Myers Squibb Company | Alpha-(N-benzenesulfonamido)cycloalkyl derivatives |
| EP2485416A4 (en) | 2009-10-02 | 2017-04-05 | LG Electronics Inc. | Transmission method and device for a downlink reference signal |
| NZ613167A (en) * | 2010-12-16 | 2015-09-25 | Univ Texas | Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds |
| US9364433B2 (en) | 2011-04-28 | 2016-06-14 | Borje S. Andersson | Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same |
| US20130302414A1 (en) * | 2012-05-07 | 2013-11-14 | Bristol-Myers Squibb Company | Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| WO2020169738A1 (en) * | 2019-02-22 | 2020-08-27 | Janssen Pharmaceutica Nv | Pharmaceutical formulations |
| BR112021019799A2 (pt) | 2019-04-11 | 2021-12-07 | Janssen Pharmaceutica Nv | Derivados contendo anéis de piridina como inibidores de malt1 |
| JP2023538099A (ja) * | 2020-08-21 | 2023-09-06 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍａｌｔ１阻害剤と、ポリエチレングリコールの脂肪酸との混合物と、を含む、医薬製剤 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5274094A (en) | 1990-08-15 | 1993-12-28 | British Bio-Technology Limited | Production of heterobicyclic containing benzene sulfonamides |
| GB9202791D0 (en) | 1992-02-11 | 1992-03-25 | British Bio Technology | Compounds |
| NZ321293A (en) | 1995-11-17 | 2001-04-27 | Warner Lambert Co | Sulfonamide inhibitors of matrix metalloproteinases |
| CZ16899A3 (cs) | 1996-07-22 | 1999-08-11 | Monsanto Company | Thiolsulfonamidové inhibitory metaloproteázy |
| CA2264718C (en) * | 1996-09-01 | 2006-05-30 | Pharmos Corporation | Solid coprecipitates for enhanced bioavailability of lipophilic substances |
| JPH11343279A (ja) | 1998-03-16 | 1999-12-14 | Shionogi & Co Ltd | スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤 |
| US6313123B1 (en) | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
| JP2002535386A (ja) | 1999-01-27 | 2002-10-22 | アメリカン・サイアナミド・カンパニー | アセチレンスルホンアミドチオールｔａｃｅインヒビター |
| NZ514453A (en) | 1999-02-26 | 2003-04-29 | Merck & Co Inc | Novel sulfonamide compounds and uses thereof |
| DE60233150D1 (de) * | 2001-10-19 | 2009-09-10 | Isotechnika Inc | Neue cyclosporin-analoge mikroemulsionsvorkonzentrate |
| NZ533603A (en) | 2001-12-20 | 2007-02-23 | Bristol Myers Squibb Co | Alpha-(N-sulphonamido)acetamide derivatives as beta-amyloid inhibitors used for treating Alzheimer's Disease and Down's syndrome |
| RU2342374C2 (ru) | 2003-03-31 | 2008-12-27 | Уайт | Фтор- и трифторалкилсодержащие гетероциклические сульфонамидные ингибиторы образования бета-амилоида и их производные |
| RU2364587C2 (ru) | 2003-10-29 | 2009-08-20 | Элан Фармасьютикалз, Инк. | N-замещенные бензолсульфонамиды |
| US7163942B2 (en) | 2004-04-01 | 2007-01-16 | Pfizer Inc. | Sulfonamide compounds for the treatment of neurodegenerative disorders |
| EP1744731A1 (en) * | 2004-04-28 | 2007-01-24 | Procarrier, Inc. | Oral formulation for delivery of poorly absorbed drugs |
| JP4845883B2 (ja) | 2004-07-13 | 2011-12-28 | エフ．ホフマン−ラ ロシュ アーゲー | スルホンアミド誘導体 |
| US7144894B2 (en) | 2004-09-23 | 2006-12-05 | Bristol-Myers Squibb Company | Sulfonamide bicyclic compounds |
| JP2008523146A (ja) * | 2004-12-14 | 2008-07-03 | ワイス | 神経変性障害の処置および予防のための５−ｈｔ６アゴニストの使用 |
| TW200732295A (en) | 2006-02-17 | 2007-09-01 | Wyeth Corp | Selective N-sulfonylation of 2-amino trifluoroalkyl substituted alcohols |
| PE20080169A1 (es) | 2006-02-17 | 2008-04-11 | Wyeth Corp | Metodo para preparar alcoholes sustituidos con sulfonamidas y sus compuestos intermedios |
| WO2007103683A2 (en) * | 2006-03-01 | 2007-09-13 | Roskamp Research Llc | Compounds for inhibiting beta-amyloid production |
| US8633179B2 (en) | 2007-03-13 | 2014-01-21 | The Trustees Of Columbia University In The City Of New York | Synergistic interaction of NOTCH-1 inhibitors with glucocorticoids |
| WO2009005688A2 (en) | 2007-06-29 | 2009-01-08 | Trustees Of Columbia University In The City Of New York | Activating mutations in notch-1 |
| US8084477B2 (en) | 2007-10-31 | 2011-12-27 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
| WO2009137657A1 (en) | 2008-05-08 | 2009-11-12 | Bristol-Myers Squibb Company | 2-aryl glycinamide derivatives |
| KR20110133046A (ko) | 2009-03-19 | 2011-12-09 | 브리스톨-마이어스 스큅 컴퍼니 | 베타 아밀로이드 펩티드 생성의 억제제로서의 신규 알파-(ｎ-술폰아미도)아세트아미드 화합물 |
| US8044077B2 (en) | 2009-03-19 | 2011-10-25 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production |
| US7977362B2 (en) | 2009-03-20 | 2011-07-12 | Bristol-Myers Squibb Company | Alpha-(N-benzenesulfonamido)cycloalkyl derivatives |
| US20110071199A1 (en) | 2009-03-20 | 2011-03-24 | Bristol-Myers Squibb Company | Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease |
| TW201043269A (en) | 2009-04-14 | 2010-12-16 | Bristol Myers Squibb Co | Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
-
2010
- 2010-04-12 US US12/758,385 patent/US8252821B2/en not_active Expired - Fee Related
- 2010-04-13 BR BRPI1015483A patent/BRPI1015483A2/pt not_active IP Right Cessation
- 2010-04-13 CN CN2010800164919A patent/CN102395361A/zh active Pending
- 2010-04-13 EA EA201101286A patent/EA201101286A1/ru unknown
- 2010-04-13 MX MX2011010514A patent/MX2011010514A/es active IP Right Grant
- 2010-04-13 EP EP10714418A patent/EP2419090B1/en not_active Not-in-force
- 2010-04-13 JP JP2012506123A patent/JP2012524092A/ja active Pending
- 2010-04-13 KR KR1020117024036A patent/KR20120022766A/ko not_active Withdrawn
- 2010-04-13 AU AU2010236602A patent/AU2010236602A1/en not_active Abandoned
- 2010-04-13 CA CA2758847A patent/CA2758847A1/en not_active Abandoned
- 2010-04-13 NZ NZ595335A patent/NZ595335A/xx not_active IP Right Cessation
- 2010-04-13 WO PCT/US2010/030862 patent/WO2010120755A1/en not_active Ceased
- 2010-04-14 AR ARP100101257A patent/AR076305A1/es not_active Application Discontinuation
- 2010-04-14 TW TW099111671A patent/TW201041609A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20100260837A1 (en) | 2010-10-14 |
| TW201041609A (en) | 2010-12-01 |
| BRPI1015483A2 (pt) | 2016-04-26 |
| JP2012524092A (ja) | 2012-10-11 |
| CN102395361A (zh) | 2012-03-28 |
| AR076305A1 (es) | 2011-06-01 |
| WO2010120755A1 (en) | 2010-10-21 |
| NZ595335A (en) | 2013-03-28 |
| CA2758847A1 (en) | 2010-10-21 |
| AU2010236602A1 (en) | 2011-10-13 |
| EP2419090A1 (en) | 2012-02-22 |
| US8252821B2 (en) | 2012-08-28 |
| MX2011010514A (es) | 2011-11-29 |
| EP2419090B1 (en) | 2013-02-13 |
| KR20120022766A (ko) | 2012-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201101286A1 (ru) | Композиции биодоступных капсул некристаллического соединения альфа-(n-сульфонамидо)ацетамина | |
| EA200901319A1 (ru) | Композиции для назального введения | |
| EA200870219A1 (ru) | Стабилизированные сукцинатом витамина е фармацевтические композиции, способы их получения и применения | |
| DE602006014990D1 (de) | Intranasale verabreichung von schnell wirkendem insulin | |
| WO2011014850A3 (en) | Topical eutectic-based formulations | |
| EA201390783A1 (ru) | Биоразлагаемые композиции для доставки лекарственных средств | |
| WO2009043049A3 (en) | Pharmaceutical formulations | |
| PL1940249T3 (pl) | Nowe formulacje rozpuszczalnych w tłuszczach składników aktywnych o wysokiej biodostępności | |
| MY174001A (en) | Self micro-emulsifying oral pharmaceutical composition of hydrophilic drug and preparation method thereof | |
| CL2011000170A1 (es) | Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa. | |
| WO2009072007A3 (en) | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof | |
| SG194756A1 (en) | Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids | |
| ZA200809864B (en) | Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic | |
| NO20080220L (no) | Formuleringer med hoy medikament belastning og doseringsformer | |
| EA200870545A1 (ru) | Новые гетероциклические соединения | |
| FR2949062B1 (fr) | Nouvelles formulations pharmaceutiques contre le mesusage des medicaments | |
| NO20054555D0 (no) | Farmasoytiske preparater som omfatter syrestabilisert insulin | |
| CY1113462T1 (el) | Μορφη δοσολογιας περιεχουσα παντοπραζολη ως δραστικο συστατικο | |
| WO2010127205A3 (en) | Fixed dose drug combination formulations | |
| EA201201202A1 (ru) | Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана | |
| WO2007044906A3 (en) | Compositions and methods for enhanced gastrointestinal stability of oligopeptides and polypeptides | |
| WO2009060952A1 (ja) | 新規製剤 | |
| WO2006002077A3 (en) | Stable pharmaceutical formulations of benzimidazole compounds | |
| WO2005107709A3 (en) | Softgel encapsulated pharmaceutical compositions comprising concentrated active ingredients | |
| WO2007100282A8 (en) | New salts of an indole derivative and their use in medicine |